Leerink Partnrs Weighs in on Sanofi’s Q2 2024 Earnings (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) – Equities research analysts at Leerink Partnrs decreased their Q2 2024 earnings per share estimates for shares of Sanofi in a note issued to investors on Tuesday, April 16th. Leerink Partnrs analyst D. Risinger now expects that the company will post earnings of $0.91 per share for the quarter, down from their previous estimate of $0.93. The consensus estimate for Sanofi’s current full-year earnings is $4.15 per share. Leerink Partnrs also issued estimates for Sanofi’s Q3 2024 earnings at $1.30 EPS, Q4 2024 earnings at $0.82 EPS, FY2026 earnings at $4.78 EPS and FY2027 earnings at $5.00 EPS.

A number of other equities research analysts have also recently commented on the stock. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. TheStreet lowered Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. Finally, Morgan Stanley assumed coverage on Sanofi in a research note on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 target price on the stock. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $55.00.

Sanofi Stock Up 2.0 %

NASDAQ:SNY opened at $46.30 on Friday. The company’s 50-day simple moving average is $47.52 and its 200-day simple moving average is $48.62. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $57.82. The stock has a market capitalization of $117.12 billion, a P/E ratio of 19.62, a P/E/G ratio of 1.72 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, February 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.94 by ($0.05). The company had revenue of $11.76 billion during the quarter, compared to analysts’ expectations of $13.02 billion. Sanofi had a net margin of 12.56% and a return on equity of 27.47%.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be paid a dividend of $1.478 per share. This is a positive change from Sanofi’s previous annual dividend of $1.38. The ex-dividend date is Thursday, May 9th. This represents a yield of 2.98%. Sanofi’s dividend payout ratio is presently 58.47%.

Institutional Investors Weigh In On Sanofi

Institutional investors and hedge funds have recently made changes to their positions in the stock. Rise Advisors LLC increased its position in shares of Sanofi by 98.4% in the 4th quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after acquiring an additional 251 shares during the period. SRS Capital Advisors Inc. grew its stake in Sanofi by 289.1% during the 1st quarter. SRS Capital Advisors Inc. now owns 463 shares of the company’s stock valued at $25,000 after purchasing an additional 344 shares during the last quarter. Householder Group Estate & Retirement Specialist LLC acquired a new position in shares of Sanofi in the third quarter valued at about $26,000. Fairfield Bush & CO. purchased a new position in shares of Sanofi in the first quarter worth about $26,000. Finally, Salem Investment Counselors Inc. acquired a new stake in shares of Sanofi during the fourth quarter worth about $27,000. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.